Sanofi: positive results for Dupixent in children
(CercleFinance.com) - Sanofi indicates that a pivotal phase-III trial of its Dupixent (dupilumab) has reached the primary and secondary endpoint in children aged six to 11 years suffering from moderate to severe asthma.
A significant reduction has been observed in the number of severe asthma attacks, attaining 65% over a year as compared to placebo, and a significant and rapid improvement of the respiratory function in a space of two weeks, maintained up to 52 weeks.
Adding that the results “confirm the known safety profile of Dupixent”, Sanofi anticipates regulatory applications between now and the first quarter of 2021 in the United States and in the European Union for children aged between six and 11 years.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
A significant reduction has been observed in the number of severe asthma attacks, attaining 65% over a year as compared to placebo, and a significant and rapid improvement of the respiratory function in a space of two weeks, maintained up to 52 weeks.
Adding that the results “confirm the known safety profile of Dupixent”, Sanofi anticipates regulatory applications between now and the first quarter of 2021 in the United States and in the European Union for children aged between six and 11 years.
Copyright (c) 2020 CercleFinance.com. All rights reserved.